Skip to content

Lobbying by Pharmascience Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Pharmascience Inc.

Meetings this Parliament
175
With MPs
20
Since Nov 2021
212
Active registrations
1

Most recent reported meeting: Oct 13, 2026.

Who they meet

Since the current Parliament opened.

MPs

Institutions

  • Innovation, Science and Economic Development Canada (ISED)93
  • Health Canada (HC)33
  • House of Commons31
  • Public Services and Procurement Canada (PSPC)11
  • Finance Canada (FIN)9
  • Global Affairs Canada (GAC)7
  • Privy Council Office (PCO)6
  • Public Safety Canada (PS)1

Registrations in effect

In-house (corporation) In effect since Oct 20, 2026 Receives government funding

Filed by David Goodman, Chief Executive Officer

Lobbyists

  • David Goodman · Executive Chairman
  • Julie Seïde · Director, Government Affairs
  • Ken Gagnon · Senior Manager, Government Affairs
  • Morris Goodman · Co-Founder

Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Services and Procurement Canada (PSPC), Transport Canada (TC)

What they're lobbying on (8)
  • Policies aimed at reinforcing pharmaceutical supply chain.
  • Discussion regarding the launch of new branded product in the rare disease space
  • Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
  • Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
  • Policies aimed at facilitating generic drug repurposing.
  • Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
  • Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
  • Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.

Registration 725814-234102-38. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by David Goodman (205), Martin Arès (7).

  • Reported by David Goodman · In-house (corporation)

    • Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
    • Miro Froehlich · Directeur des politiques, Privy Council Office (PCO)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Miro Froehlich · Directeur des politiques, Privy Council Office (PCO)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Mahamat Djalal · Conseiller principal du Québec, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Éric Sabourin · Analyste princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
    • catherine Martinelli · Business Risk Analyst, Innovation, Science and Economic Development Canada (ISED)
    • Alhadji Mamat · Gestionnaire princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Jacques Ramsay · Député
    • Marjorie Michel · Ministre de la Santé, Health Canada (HC)
    • Alizée Rivalta · Adjointe aux communications, House of Commons
    • Joël Raby Fernandes · Adjoint parlementaire, House of Commons
    and 2 more
    • Fatoumata Bah · Conseillere en politiques, Health Canada (HC)
    • Mahamat Djalal · Conseiller principal du Québec, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Éric Sabourin · Analyste princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Erin Campbell · Directrice, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Joël Raby Fernandes · Adjoint parlementaire, House of Commons
    • Jean-Sébastien Côté · Gestionnaire de bureau, House of Commons
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Joël Raby Fernandes · Adjoint parlementaire, House of Commons
    • Jean-Sébastien Côté · Gestionnaire de bureau, House of Commons
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Justine Frame · Conseillère en politiques, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Éric Sabourin · Analyste princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Joël Raby Fernandes · Adjoint parlementaire, House of Commons
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Éric Sabourin · Analyste princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Kathy Frankiewicz · adjointe administrative, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Joël Raby Fernandes · Adjoint parlementaire, House of Commons
    Policies aimed at facilitating generic drug repurposing.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Justine Frame · Conseillère en politiques, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Justine Frame · Conseillère en politiques, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Élyse Moisan · Conseiller politique, Finance Canada (FIN)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.